Evaluation of sleep pattern disorders in breast cancer patients receiving adjuvant treatment (chemotherapy and/or radiotherapy) using polysomnography

被引:5
|
作者
Eldin, El-Sayed Tag [1 ]
Younis, Samar Galal [2 ]
Abd El Aziz, Lamiss Mohamed [2 ]
Eldin, Amr Tag [3 ]
Erfan, Sherif Tarek [3 ]
机构
[1] Tanta Univ Hosp, Dept Neurol, Tanta, Gharbia, Egypt
[2] Tanta Univ Hosp, Dept Clin Oncol, Tanta, Gharbia, Egypt
[3] Tanta Univ Hosp, Tanta, Gharbia, Egypt
来源
JOURNAL OF BUON | 2019年 / 24卷 / 02期
关键词
breast cancer; non-rapid eye movement; total sleep time; insomnia severity index; QUALITY; WOMEN; DISTURBANCES; SURVIVORS; INDEX;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess sleep disturbance patterns in breast cancer patients receiving adjuvant radiotherapy and/or chemotherapy in comparison to normal subjects, and their impact on quality of life. Methods: Seventy-four histologically proven breast cancer patients of both genders, aged 30 to 65 years, were classified into 2 groups. First group: 26 patients with breast cancer before receiving any treatment. Second group: 48 breast cancer patients, subdivided into group A (24 patients with adjuvant chemotherapy), and group B (24 patients with adjuvant radiotherapy). A control group consisted of 24 healthy individuals matched in age and sex with patient groups. Clinical assessment of sleep was done using the Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) and one night Polysomnography (NPSG). Results: No statistically significant difference regarding age and sex was found compared to control group. The severity of insomnia (ISI) was 29.2%, 4.2%, 7.7% and 0% for patients who received chemotherapy and/or radiotherapy, and comparison of patients without treatment and the control group showed statistical significance. Excessive daytime sleepiness was 37.5%, 25%, 26.9% and 0% for patients who received chemotherapy and/or radiotherapy, before receiving treatment, and the control groups respectively, the difference been significant. Comparison of patients who received treatment with those who did not and the control groups showed significant shortening of total sleep time, decrease of sleep efficiency and lengthening of sleep latency. Significant lengthening in stage 2 of non-rapid eye movement (NREM), while insignificant lengthening in stages 1, 3 and 4 of NREM sleep was noted. Significant reduction of rapid eye movement (REM) and total sleep time percentage were observed. Sleep apnea was insignificantly more common in breast cancer patients compared to healthy controls. Conclusion: Sleep-related changes in breast cancer patients should be used in planning best supportive care.
引用
收藏
页码:529 / 534
页数:6
相关论文
共 50 条
  • [21] QUALITY OF LIFE FOR BREAST-CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    MEYEROWITZ, BE
    WATKINS, IK
    SPARKS, FC
    AMERICAN JOURNAL OF NURSING, 1983, 83 (02) : 232 - 235
  • [22] Prevalence and course of fatigue in breast cancer patients receiving adjuvant chemotherapy
    de Jong, N
    Candel, MJJM
    Schouten, HC
    Abu-Saad, HH
    Courtens, AM
    ANNALS OF ONCOLOGY, 2004, 15 (06) : 896 - 905
  • [23] Energy Balance in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy
    Michelle N. Harvie
    I.T. Campbell
    A. Baildam
    A. Howell
    Breast Cancer Research and Treatment, 2004, 83 : 201 - 210
  • [24] LYMPHOCYTE CYTOGENETICS IN BREAST-CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
    STEPHAN, EJ
    TATTERSALL, MHN
    BAKER, RSU
    GILLIES, CB
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1983, 10 (04) : 434 - 434
  • [25] Energy balance in early breast cancer patients receiving adjuvant chemotherapy
    Harvie, MN
    Campbell, IT
    Baildam, A
    Howell, A
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (03) : 201 - 210
  • [26] Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
    Melchior, Nicole M.
    Sachs, Darren B.
    Gauvin, Gabrielle
    Chang, Cecilia
    Wang, Chihsiung E.
    Sigurdson, Elin R.
    Daly, John M.
    Aggon, Allison A.
    Hayes, Shelly B.
    Obeid, Elias I.
    Bleicher, Richard J.
    CANCER MEDICINE, 2020, 9 (08): : 2742 - 2751
  • [27] Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Hurria, A
    Brogan, K
    Panageas, KS
    Pearce, C
    Norton, L
    Jakubowski, A
    Zauderer, M
    Howard, J
    Hudis, C
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 92 (02) : 151 - 156
  • [28] ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN BREAST-CANCER
    MCARDLE, CS
    CRAWFORD, D
    DYKES, EH
    CALMAN, KC
    HOLE, D
    RUSSELL, AR
    SMITH, DC
    BRITISH JOURNAL OF SURGERY, 1986, 73 (04) : 264 - 266
  • [29] Breast cancer in elderly patients. Value of adjuvant chemotherapy and radiotherapy
    Eucker, J.
    Matuschek, C.
    Budach, W.
    Possinger, K.
    ONKOLOGE, 2007, 13 (09): : 831 - +
  • [30] Evaluation of cognitive function and quality of life in breast cancer patients receiving adjuvant dose dense chemotherapy
    Dabrow, Michael B.
    Szarka, Christine E.
    Moore, Joanne
    Chernick, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)